BioDelivery Sciences International Inc. (NASDAQ:BDSI)’s share price fell 5.3% during mid-day trading on Monday . The company traded as low as $2.48 and last traded at $2.48, with a volume of 382,238 shares traded. The stock had previously closed at $2.62.

A number of brokerages have issued reports on BDSI. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Tuesday, July 5th. Janney Montgomery Scott reaffirmed a “hold” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. Roth Capital reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a report on Monday, March 28th. Finally, FBR & Co reaffirmed a “positive” rating and issued a $12.00 target price on shares of BioDelivery Sciences International in a report on Tuesday, March 29th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $8.25.

The firm’s market cap is $134.52 million. The company’s 50 day moving average is $2.45 and its 200 day moving average is $3.20.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01. The business earned $3 million during the quarter, compared to analysts’ expectations of $2.96 million. During the same period in the prior year, the company earned ($0.16) EPS. BioDelivery Sciences International’s quarterly revenue was down 77.1% on a year-over-year basis. Equities research analysts forecast that BioDelivery Sciences International Inc. will post ($1.19) earnings per share for the current year.

Several hedge funds have made changes to their positions in BDSI. Sei Investments Co. raised its stake in shares of BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after buying an additional 233,519 shares during the period. 1492 Capital Management LLC raised its stake in shares of BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock worth $2,580,000 after buying an additional 41,069 shares during the period. Bank of Montreal Can raised its stake in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock worth $3,971,000 after buying an additional 28,838 shares during the period. Turner Investments L.P. raised its stake in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock worth $4,315,000 after buying an additional 321,290 shares during the period. Finally, Russell Frank Co raised its stake in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock worth $5,151,000 after buying an additional 394,272 shares during the period.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.